We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
Cap. Flow
+$1.13B
Cap. Flow %
11.96%
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$51.9M
2
MRK icon
Merck
MRK
+$50.9M
3
DHR icon
Danaher
DHR
+$45.3M
4
TMO icon
Thermo Fisher Scientific
TMO
+$37.8M
5
JD icon
JD.com
JD
+$37.7M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$103M
2
BABA icon
Alibaba
BABA
+$98.6M
3
CRM icon
Salesforce
CRM
+$62.5M
4
BMY icon
Bristol-Myers Squibb
BMY
+$59.4M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$48.6M

Sector Composition

Rank Sector Weight
1 Healthcare 34.61%
2 Technology 20.94%
3 Consumer Discretionary 8.9%
4 Financials 8.59%
5 Communication Services 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRB icon
801
H&R Block
HRB
$5.37B
– –
-22,949
Closed -$527K
HUBB icon
802
Hubbell
HUBB
$26.3B
– –
-2,676
Closed -$387K
PPLI
803
People Inc
PPLI
$3.15B
– –
-27,680
Closed -$1.21M
ING icon
804
ING
ING
$95.7B
– –
-111
Closed -$1K
IRTC icon
805
iRhythm Holdings
IRTC
$3.69B
– –
-13,000
Closed -$865K
IVZ icon
806
Invesco
IVZ
$13.3B
– –
-75,497
Closed -$1.52M
JEF icon
807
Jefferies Financial Group
JEF
$13B
– –
-80,887
Closed -$1.61M
KRC icon
808
Kilroy Realty
KRC
$4.58B
– –
-2,582
Closed -$212K
KSS icon
809
Kohl's
KSS
$2.1B
– –
-54,208
Closed -$2.7M
LEG icon
810
Leggett & Platt
LEG
$1.5B
– –
-5,468
Closed -$272K
LII icon
811
Lennox International
LII
$19B
– –
-3,718
Closed -$887K
MAN icon
812
ManpowerGroup
MAN
$2.5B
– –
-2,090
Closed -$198K
MOMO
813
Hello Group
MOMO
$869M
– –
-18,700
Closed -$612K
NCLH icon
814
Norwegian Cruise Line
NCLH
$9.2B
– –
-15,038
Closed -$859K
NOV icon
815
NOV
NOV
$7.35B
– –
-30,126
Closed -$738K
NWL icon
816
Newell Brands
NWL
$2.2B
– –
-35,034
Closed -$658K
PACB icon
817
Pacific Biosciences
PACB
$422M
– –
-411,991
Closed -$2.07M
PBYI icon
818
Puma Biotechnology
PBYI
$407M
– –
-82,200
Closed -$703K
PKX icon
819
POSCO
PKX
$16.1B
– –
-7,020
Closed -$347K
PNQI icon
820
Invesco NASDAQ Internet ETF
PNQI
$514M
– –
-24,500
Closed -$679K
PNR icon
821
Pentair
PNR
$10.2B
– –
-46
Closed -$1K
PUK icon
822
Prudential
PUK
$36.6B
– –
-44,790
Closed -$1.62M
QTRX icon
823
Quanterix
QTRX
$173M
– –
-31,000
Closed -$716K
RARE icon
824
Ultragenyx Pharmaceutical
RARE
$2.65B
– –
-121,500
Closed -$5.07M
RDNT icon
825
RadNet
RDNT
$4.84B
– –
-256,392
Closed -$5.09M
31 32
33
34 35

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q2 2020 Portfolio in Review

As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.

  • Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
  • Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
  • Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
  • Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
  • Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
  • Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
  • Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.

Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.